Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07388888
Starting soon Phase 4

Antibacterial Effect of Two Different Intracanal Medicaments and Their Effect on Post-operative Pain

NCT07388888 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2026-02
Last updated
2026-02-05

Condition(s) studied

Pulp Necrosis

Investigational drug(s) / intervention(s)

Calcium Hydroxide (Ca(OH)2) →chitosan nanoparticles gel

Calcium Hydroxide (Ca(OH)2): Non setting calcium hydroxide intracanal medicament is injected through the root canal for two weeks

chitosan nanoparticles gel: Nano chitosan gel is injected through the root canal as an intracanal medicament for two weeks

Study summary

Evaluation of antibacterial effect of two different intracanal medicaments on bacterial load in infected mature permanent teeth and their effect on post-operative pain level.

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * free medical history, * mature infected permanent single rooted teeth diagnosed clinically and radiographically with adequate coronal structure for proper isolation, temporization and restoration. Exclusion Criteria: * Patients who are not included in the age range of the study or having a systemic condition. * Teeth with severe fractures or resorption or periodontally compromised.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry Ain Shams University Cairo Egypt

More Ain Shams University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07388888 on ClinicalTrials.gov ↗ ← All trials in Egypt